References
- Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516–the Southwest Oncology Group. J Clin Oncol 2009;27:114–119.
- van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178–1184.
- Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129–133.
- Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 2014;55:2228–2240.
- Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
- Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116:4283–4290.
- Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 2012;118:2944–2951.
- Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2014;55:509–514.
- Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood 2014;124(Suppl. 1): Abstract 394.
- Uni M, Kagoya Y, Nannya Y, et al. Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors. Leuk Lymphoma 2015;56:1869–1871.
- Hegde U. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105:496–502.
- Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009;27:1462–1469.
- Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014;99:1228–1235.
- Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012;120: 3222–3228.
- Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014;166:891–901.
- Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. Blood 2014;124:2354–2361.
- Savage KJ, Sehn LH, Villa D, et al. The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL). Blood 2014;124(Suppl. 1): Abstract 495.
- Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417–1429.
- Chapuy B, Roemer MG, Tan Y, et al. Actionable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2014;124(Suppl. 1): Abstract 74.